{
  "$schema": "folio-library-entry/v1",
  "id": "10665-258516",
  "blocks": [
    {
      "id": "library/10665-258516/blocks/figure-img-p001-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-1.webp",
      "narrative": "draft",
      "content": "Photograph of a health worker's gloved hands holding a labelled blood sample tube, with a young woman seated in the background.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 4,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO IMPLEMENTATION \nTOOL FOR PRE-EXPOSURE \nPROPHYLAXIS (PrEP)  \nOF HIV INFECTION\nTESTING \nPROVIDERS\nMODULE 10\nJULY 2017\nWHO/HIV/2017.30\n© World Health Organization 2017\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO \nlicence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). \nUnder the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work \nis appropriately cited, as indicated below. In any use of this work, there should be no suggestion",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of WHO's PrEP implementation tool, Module 10 for testing providers (July 2017), with the copyright and licence page, citation and disclaimers, abbreviations and the table of contents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "INTRODUCTION",
      "pageStart": 4,
      "pageEnd": 6,
      "target": "../sections/sec-000-introduction.md",
      "narrative": null,
      "content": "Following the WHO recommendation in September 2015 that “oral pre-exposure prophylaxis (PrEP) should be offered as \nan additional prevention choice for people at substantial risk of HIV infection as part of combination HIV prevention \napproaches”, partners in countries expressed the need for practical advice on how to consider the introduction of PrEP and \nstart implementation. In response, WHO has developed this series of modules to support the implementation of PrEP \namong a range of populations in different settings.  \nAlthough there is growing acknowledgement of PrEP’s potential as an addi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces WHO's series of implementation modules on oral pre-exposure prophylaxis (PrEP), produced after the 2015 recommendation that PrEP be offered to people at substantial HIV risk. It stresses that PrEP should complement, not replace, condoms and harm reduction, that key populations may face barriers, and that the choice to use PrEP rests with the individual. It outlines the target audience, guiding principles based on public health and human rights, and summarises each module and supporting resources.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "THE TESTING PROVIDERS MODULE",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/sec-001-the-testing-providers-module.md",
      "narrative": null,
      "content": "This module is designed to support national HIV programme managers and other decision-makers who have an interest in \nimplementing pre-exposure prophylaxis (PrEP) and require guidance in selecting the relevant testing services, including \nappropriate screening of clients before PrEP is initiated and monitoring while taking PrEP. Information is provided on \ntesting for HIV, creatinine, hepatitis B virus (HBV), hepatitis C virus (HCV), pregnancy and sexually transmitted infections \n(STIs) such as Treponema pallidum (syphilis), Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). \nThis modu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the testing providers module helps programme managers choose testing services for screening before and monitoring during PrEP, covering HIV, creatinine, hepatitis B and C, pregnancy and sexually transmitted infections. It restates WHO's strong recommendation that oral PrEP containing TDF be offered to people at substantial risk.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Key messages: testing services in the context of PrEP",
      "pageStart": 6,
      "pageEnd": 8,
      "target": "../sections/sec-002-key-messages-testing-services-in-the-context-of.md",
      "narrative": null,
      "content": "Several testing services must be delivered before a person can start taking PrEP safely and effectively. Periodic retesting \nwhile a person is taking PrEP is also needed. (See Table 1 below for a summary of suggested testing services for \nindividuals starting and taking PrEP.)\nTesting for HIV is required to rule out infection prior to initiating PrEP. Once an individual has been initiated on PrEP, HIV \ntesting is suggested every three months and whenever restarting PrEP after a gap in use to rule in or rule out HIV \ninfection. Some services and programmes are currently conducting an additional",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the key testing messages for PrEP: HIV testing before starting and every three months, plus suggested creatinine, hepatitis B and C, pregnancy and STI testing. A table sets out each test, its timing and setting, including the preference for nucleic acid tests for gonorrhoea and chlamydia and syndromic management where these are unavailable.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "TABLE 1. SUMMARY OF TESTING SERVICES FOR STARTING AND MONITORING PREP",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "Laboratory and point-of-care tests for people starting and using HIV pre-exposure prophylaxis (PrEP): for each pathogen or analyte (HIV, creatinine, hepatitis B and C, pregnancy, syphilis, gonorrhoea and chlamydia) the table gives where testing can be done and its timing and frequency.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "HIV testing services",
      "pageStart": 8,
      "pageEnd": 13,
      "target": "../sections/sec-003-hiv-testing-services.md",
      "narrative": null,
      "content": "All people at substantial risk of HIV infection who could be eligible for PrEP should be offered HIV testing services. Prior to \nstarting or restarting PrEP, it is critical to rule in or rule out HIV infection in order to: \ni) Identify and diagnose people with HIV; \nii) Refer and link people with HIV to treatment and care as early as possible; \niii) Ensure people who have HIV do not start PrEP (3–5). \nHIV testing services prior to and throughout PrEP use can be delivered in a variety of settings, depending on the type of \ntest being performed (see Fig. 1). \nProviding an HIV diagnosis in the co",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes HIV testing services before and during PrEP, explaining why ruling HIV in or out matters and how national algorithms using rapid tests apply in high and low prevalence settings. It covers handling discrepant results, acute infection, testing levels and staff qualifications across the health system, with flow diagrams. It closes by discussing rare infections with drug-resistant HIV despite PrEP and the need for surveillance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Kidney function monitoring",
      "pageStart": 13,
      "pageEnd": 13,
      "target": "../sections/sec-004-kidney-function-monitoring.md",
      "narrative": null,
      "content": "Creatinine testing\nIt is suggested that serum creatinine testing be done prior to PrEP initiation and throughout the first year (every six \nmonths) of taking PrEP. After the first year, testing could be conducted less frequently. The use of PrEP containing TDF is \nassociated in some people with a small decrease in estimated creatinine clearance, which occurs within months after \nstarting PrEP. Based on the available evidence, this decrease does not usually progress during PrEP use and generally \nreverses after stopping PrEP (21–23). There is limited information about the optimal timing and fre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Advises serum creatinine testing before PrEP and every six months in the first year, noting that TDF can cause a small, usually reversible fall in creatinine clearance. It identifies people needing closer monitoring and describes laboratory and point-of-care testing options.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Hepatitis B testing",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-005-hepatitis-b-testing.md",
      "narrative": null,
      "content": "Hepatitis B surface antigen (HBsAg) testing \nScreening for chronic HBV infection should be considered for people starting or restarting PrEP.\nChronic HBV infection is defined as the persistence of HBsAg for more than six months. Assays for HBsAg may be \nconducted at the point of care or within a laboratory (see Fig. 5). Testing for HBsAg as a marker of chronic HBV infection is \nwarranted, particularly where there is a high prevalence of HBV infection or poor coverage of HBV immunization. \nStarting and stopping PrEP has been found to be safe in people with active HBV infection and no sign of cl",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends considering hepatitis B surface antigen screening for people starting or restarting PrEP, especially where HBV is common or vaccination coverage is low. It explains the benefits of screening and how TDF-based PrEP interacts with HBV treatment, including the risk of flare if PrEP is stopped.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Hepatitis C testing",
      "pageStart": 14,
      "pageEnd": 16,
      "target": "../sections/sec-006-hepatitis-c-testing.md",
      "narrative": null,
      "content": "Consideration could be given to testing for evidence of HCV infection in men who have sex with men and people who \ninject drugs prior to initiation of PrEP and every 12 months thereafter (23). \nTesting for evidence of HCV infection is typically conducted by using a serological assay to detect antibodies to HCV \n(anti-HCV). However, evidence of anti-HCV alone is not indicative of active HCV infection as 15–45% of HCV infections \nare spontaneously resolved within six months but anti-HCV may persist for an undetermined period of time.  Furthermore, \nexpanded access to antiviral treatment may lead",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Suggests hepatitis C testing for people who inject drugs and men who have sex with men before PrEP and yearly thereafter. It explains why antibody tests alone do not show current infection and presents an algorithm using HCV RNA or core antigen testing to confirm it.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pregnancy testing",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-007-pregnancy-testing.md",
      "narrative": null,
      "content": "Testing for pregnancy can be offered to women (and transgender men) who have signs and symptoms of pregnancy and, \nwhere indicated, a referral made to antenatal services. Pregnancy is associated with a higher risk of acquiring HIV \ninfection (28). The acquisition of HIV during pregnancy can result in higher rates of mother-to-child transmission. PrEP can \nbe continued through pregnancy unless the woman chooses to stop. \nFor more information see WHO technical update on PrEP in pregnancy and breastfeeding: \nhttp://who.int/hiv/pub/toolkits/prep-preventing-hiv-during-pregnancy/en/.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that pregnancy testing can be offered to women and transgender men with signs of pregnancy, that pregnancy raises HIV risk, and that PrEP can continue through pregnancy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Testing for sexually transmitted infections",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-008-testing-for-sexually-transmitted-infections.md",
      "narrative": null,
      "content": "PrEP provides an opportunity for regular screening for common STIs, including syphilis, gonorrhoeae and chlamydial \ninfections. Where possible, programmes should expand and implement relevant national guidelines on STI screening \namong people starting or taking PrEP.\nAdditional guidance on STI screening can be found in the WHO manual Laboratory diagnosis of sexually transmitted \ninfections, including human immunodeficiency virus (29).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that PrEP visits offer a chance for regular screening for syphilis, gonorrhoea and chlamydia in line with national guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Syphilis testing",
      "pageStart": 16,
      "pageEnd": 18,
      "target": "../sections/sec-009-syphilis-testing.md",
      "narrative": null,
      "content": "People starting or restarting PrEP will likely benefit from syphilis screening and periodic retesting every three to six \nmonths while using PrEP. PrEP programmes should adhere to the relevant national testing procedures and guidelines as \nconducted within existing health services. \nDepending on which assays are available and utilized in a particular setting, different testing strategies for diagnosis of \nsyphilis can be followed (see examples in Figs. 7 and 8). Where treponemal assays are used, individuals who test positive \nshould receive further testing using a nontreponemal assay to confir",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Covers syphilis screening at PrEP start and every three to six months, describing treponemal and nontreponemal assays and example testing strategies. It also addresses gonorrhoea and chlamydia testing, preferring nucleic acid tests and syndromic treatment where these are not available.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO prequalification assessment and tools for testing providers",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-010-who-prequalification-assessment-and-tools-for-te.md",
      "narrative": null,
      "content": "Both before an assay is marketed and after it is on the market, its quality, safety and performance must be assured. In \nvitro diagnostic medical devices (IVDs) are classified by regulatory authorities according to the risk they may pose to \npublic health and individual health, taking into account the potential outcomes and impact if the result is incorrect. Assays \nfor HIV and HBV (and others) usually attract the highest level of scrutiny in their pre-market assessment review, given the \nhigh impact of an incorrect result on individual and public health in terms of onward transmission. Assays",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that in vitro diagnostics are classed by risk, with HIV and HBV assays scrutinised most, and that WHO independently reviews the quality, safety and performance of diagnostics sold in resource-limited settings because regulation is often weak.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Pre-market assessment of in vitro diagnostics",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-011-pre-market-assessment-of-in-vitro-diagnostics.md",
      "narrative": null,
      "content": "WHO conducts the prequalification assessment of IVDs using a standardized procedure to determine if the products meet \nWHO prequalification requirements. The assessment consists of three key components: \n•\t review of safety, quality and performance of the IVD as presented in a product dossier prepared by the manufacturer;\n•\t desk review of the quality management systems applied during production, followed by a site inspection; \n•\t independent evaluation of performance and operational characteristics of the IVD. \nThe WHO publication Overview of the prequalification of in vitro diagnostics asses",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the three parts of WHO prequalification assessment of diagnostics: dossier review, quality-management review with site inspection, and independent performance evaluation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Post-market surveillance of in vitro diagnostics",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-012-post-market-surveillance-of-in-vitro-diagnostics.md",
      "narrative": null,
      "content": "Once a product is placed on the market, its quality, safety and performance must be monitored to ensure it continues to \nmeet standards. WHO has established a system for post-market surveillance of IVDs that supplements the obligations of \nmanufacturers, who must also conduct their own post-market evaluation activities. In this context, post-market \nsurveillance consists of:\n•\t proactive post-market surveillance (to identify any problem before use) through in-country lot verification testing, both \nbefore and after distribution of test kits to testing sites; \n•\t reactive post-market surveillan",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes WHO's post-market surveillance system for diagnostics, combining proactive lot verification testing and reactive reporting of problems, with links to guidance and the prequalified products list.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-258516/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "REFERENCES",
      "pageStart": 19,
      "pageEnd": 24,
      "target": "../sections/sec-013-references.md",
      "narrative": null,
      "content": "1.\t\nGrant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV \nprevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587-99.\n2.\t\nGrant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, et al. Drug resistance and plasma viral \nRNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331-7.\n3.\t\nLiegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, et al. HIV-1 Drug Resistance in the iPrEx \nPreexposure Prophylaxis Trial. J Infect Dis. 2014.\n4.\t\nGr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the PrEP testing providers module, citing mainly PrEP trials, HIV drug resistance studies and WHO testing guidelines, followed by WHO HIV department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
